Document Detail


Testicular cancer survivorship: research strategies and recommendations.
MedLine Citation:
PMID:  20585105     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
Testicular cancer represents the most curable solid tumor, with a 10-year survival rate of more than 95%. Given the young average age at diagnosis, it is estimated that effective treatment approaches, in particular, platinum-based chemotherapy, have resulted in an average gain of several decades of life. This success, however, is offset by the emergence of considerable long-term morbidity, including second malignant neoplasms, cardiovascular disease, neurotoxicity, nephrotoxicity, pulmonary toxicity, hypogonadism, decreased fertility, and psychosocial problems. Data on underlying genetic or molecular factors that might identify those patients at highest risk for late sequelae are sparse. Genome-wide association studies and other translational molecular approaches now provide opportunities to identify testicular cancer survivors at greatest risk for therapy-related complications to develop evidence-based long-term follow-up guidelines and interventional strategies. We review research priorities identified during an international workshop devoted to testicular cancer survivors. Recommendations include 1) institution of lifelong follow-up of testicular cancer survivors within a large cohort setting to ascertain risks of emerging toxicities and the evolution of known late sequelae, 2) development of comprehensive risk prediction models that include treatment factors and genetic modifiers of late sequelae, 3) elucidation of the effect(s) of decades-long exposure to low serum levels of platinum, 4) assessment of the overall burden of medical and psychosocial morbidity, and 5) the eventual formulation of evidence-based long-term follow-up guidelines and interventions. Just as testicular cancer once served as the paradigm of a curable malignancy, comprehensive follow-up studies of testicular cancer survivors can pioneer new methodologies in survivorship research for all adult-onset cancer.
Authors:
Lois B Travis; Clair Beard; James M Allan; Alv A Dahl; Darren R Feldman; Jan Oldenburg; Gedske Daugaard; Jennifer L Kelly; M Eileen Dolan; Robyn Hannigan; Louis S Constine; Kevin C Oeffinger; Paul Okunieff; Greg Armstrong; David Wiljer; Robert C Miller; Jourik A Gietema; Flora E van Leeuwen; Jacqueline P Williams; Craig R Nichols; Lawrence H Einhorn; Sophie D Fossa
Related Documents :
22658275 - Application of molecular techniques in the diagnosis, prognosis and management of patie...
22819905 - Thymidylate synthase and cyclin d1 protein expression in lymph node negative colorectal...
6177295 - Gynecomastia after cytotoxic therapy for metastatic testicular cancer.
22326975 - Line-1 methylation in the peripheral blood mononuclear cells of cancer patients.
25326065 - Ccr1-mediated accumulation of myeloid cells in the liver microenvironment promoting mou...
23471665 - Bladder polypoid cystitis-derived a20 associates with tumorigenesis.
Publication Detail:
Type:  Journal Article; Research Support, N.I.H., Extramural; Review     Date:  2010-06-28
Journal Detail:
Title:  Journal of the National Cancer Institute     Volume:  102     ISSN:  1460-2105     ISO Abbreviation:  J. Natl. Cancer Inst.     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-08-04     Completed Date:  2010-08-25     Revised Date:  2013-05-29    
Medline Journal Info:
Nlm Unique ID:  7503089     Medline TA:  J Natl Cancer Inst     Country:  United States    
Other Details:
Languages:  eng     Pagination:  1114-30     Citation Subset:  IM    
Affiliation:
Department of Radiation Oncology, James P. Wilmot Cancer Center, University of Rochester Medical Center, Rochester, NY 14642, USA. lois_travis@urmc.rochester.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adult
Antineoplastic Agents / administration & dosage*,  adverse effects*
Antineoplastic Combined Chemotherapy Protocols / administration & dosage,  adverse effects
Cardiovascular Diseases / chemically induced,  genetics
Clinical Trials as Topic
Cognition / drug effects
Employment
Evidence-Based Medicine
Fatigue / chemically induced
Genetic Predisposition to Disease
Genome-Wide Association Study
Humans
Infertility, Male / chemically induced,  genetics
Male
Models, Statistical
Neoplasm Recurrence, Local / prevention & control
Neoplasms, Second Primary / prevention & control
Paresthesia / chemically induced,  genetics
Platinum Compounds / administration & dosage,  adverse effects
Population Surveillance
Pulmonary Fibrosis / chemically induced,  genetics
Quality of Life
Renal Insufficiency / chemically induced,  genetics
Risk Assessment
Survival Rate
Survivors / statistics & numerical data*
Testicular Neoplasms / drug therapy*,  mortality,  psychology
Young Adult
Grant Support
ID/Acronym/Agency:
5U56CA118635/CA/NCI NIH HHS
Chemical
Reg. No./Substance:
0/Antineoplastic Agents; 0/Platinum Compounds
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Expert holistic nurses' advice to nursing students.
Next Document:  Effect of Modest Salt Reduction on Skin Capillary Rarefaction in White, Black, and Asian Individuals...